Furthermore, IDO1 is involved in the formation of resistance to immune checkpoint inhibitors [13], and the combination of an IDO1 inhibitor with checkpoint inhibitors represents an alternative strategy in cancer immunotherapy [14]. This evidence concerns the gene IDO1 and cancer.